H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma to $36 from $32 and keeps a Buy rating on the shares. The FDA approved the company’s lead candidate ensifentrine on schedule for the maintenance treatment of chronic obstructive pulmonary disease, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
- Expert likely to prescribe more ensifentrine than dupixent, says Jefferies
- Jefferies healthcare analyst holds an analyst/industry conference call
- Verona Pharma announces $650M strategic financing with Oaktree, OMERS
- Verona Pharma reports Q1 EPS (4c), consensus (16c)